Skip to search formSkip to main contentSkip to account menu

bavituximab

Known as: Chimeric Anti-Phosphotidylserine Monoclonal Antibody 
A chimeric, IgG1 monoclonal antibody directed against anionic phospholipids with potential antineoplastic activity. Bavituximab binds to anionic… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (1)

Monoclonal Antibodies
NCIt Antineoplastic Agent Terminologyantigen binding

Narrower (1)

Tarvacin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
A Phase I Clinical Trial of the Phosphatidylserine-targeting Antibody Bavituximab in Combination With Radiation Therapy and Capecitabine in the Preoperative Treatment of Rectal Adenocarcinoma
Objectives: There is interest in improving the tumoricidal effects of preoperative radiotherapy for rectal carcinoma by studying… 
2015
2015
A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer
Bavituximab is a chimeric monoclonal antibody that targets phosphatidylserine (PS). PS is externalized on cells in the tumor… 
2015
2015
Redirecting adenoviruses to tumour cells using therapeutic antibodies: Generation of a versatile human bispecific adaptor.
2015
2015
Effective Binding of a Phosphatidylserine-Targeting Antibody to Ebola Virus Infected Cells and Purified Virions
Ebola virus is responsible for causing severe hemorrhagic fevers, with case fatality rates of up to 90%. Currently, no antiviral… 
2013
2013
Catheterized guinea pigs infected with Ebola Zaire virus allows safer sequential sampling to determine the pharmacokinetic profile of a phosphatidylserine-targeting monoclonal antibody.
2013
2013
Randomized, blinded, placebo-controlled phase II trial of docetaxel and bavituximab as second-line therapy in locally advanced or metastatic non-squamous non-small cell lung cancer.
8095 Background: Bavituximab (B) is a monoclonal antibody against phosphatidylserine (PS) with a selective tumor vascular… 
2010
2010
Phase II study of bavituximab plus paclitaxel and carboplatin in untreated locally advanced or metastatic non-small cell lung cancer: Interim results.
7589 Background: Bavituximab, a novel chimeric IgG1 monoclonal antibody which targets the membrane phospholipid… 
2010
2010
Phase II study of bavituximab plus docetaxel in locally advanced or metastatic breast cancer.
1042 Background: Bavituximab, a novel IgG1 monoclonal antibody which targets membrane phosphatidylserine complexed with β2… 
2008
2008
A phase Ib safety and pharmacokinetic study of bavituximab plus chemotherapy in patients with refractory advanced solid tumor malignancies
3038 Background: Bavituximab (B) is a first in class anti-phosphatidylserine (PS) monoclonal antibody. This immunotherapeutic… 
1996
1996
Changes in the pattern of distribution of von Willebrand factor in rat aortic endothelial cells following thrombin generation in vivo
The pattern of distribution of von Willebrand factor (VWF) in relatively large sheets of rat aortic endothelial cells (EC… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)